Background Molecularly targeted agents have been reported to have anti-tumour activity for
patients whose tumours harbour the matching molecular alteration. These results have led …

Background The poly(adenosine diphosphate–ribose) inhibitor talazoparib has shown antitumor
activity in patients with advanced breast cancer and germline mutations in BRCA1 and …

Background Brain metastases occur in 30–50% of patients with metastatic HER2-positive
breast cancer. In the case of diffuse brain metastases, treatment is based on whole brain …

Brain metastases (BM) are the most common intracranial neoplasm in adults. Initially
considered as an essentially terminal stage of advanced cancer, BM are increasingly being …

Background Major advances have been achieved in the characterization of early breast cancer
(eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes…

Cancer progression is driven in part by genomic alterations 1 . The genomic characterization
of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to …

Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …

Original research: Neoadjuvant nivolumab for patients with resectable HPV-positive and
HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial - …

Paclitaxel is an antimicrotubule agent that induces mitotic block and apoptosis. We show for
the first time that paclitaxel acts directly on mitochondria isolated from human cancer cells. In …

Introduction Breast cancer is a complex and heterogeneous disease at the molecular level.
Evolution is difficult to predict according to classical histoclinical prognostic factors. Different …